The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abuse Liability of Flunitrazepam
Abstract
Flunitrazepam is among the most frequently prescribed hypnotics in many countries. Although it was never marketed in the United States, flunitrazepam, in recent years, has been smuggled into the country, and reports of abuse--including alleged use of the drug to facilitate "date rape"--have attracted a great deal of scrutiny. It has been suggested that flunitrazepam may have greater liability for abuse than other benzodiazepines; such suggestions are supported by surveys of opioid abusers, many of whom report a distinct preference for flunitrazepam over other benzodiazepines. Experimental studies of animals and normal human subjects indicate that, although flunitrazepam has high efficacy and is very potent, it is pharmacologically similar to most other benzodiazepines. Although the studies are limited in number and scope, the data show no apparent differences between flunitrazepam and other benzodiazepines in ability to produce drug-taking or drug-seeking behavior, in capacity to produce physiologic dependence, nor in the characteristics of withdrawal after administration of an antagonist or discontinuation of treatment. Similar to other benzodiazepines, flunitrazepam produces dose-dependent effects on psychomotor performance and recall. Flunitrazepam does not seem to be involved in medical emergencies more often than other benzodiazepines, and there is no indication that flunitrazepam is more toxic than other benzodiazepines when taken in overdose by drug abusers or other individuals. Survey research among typical patient populations suggests that flunitrazepam is characteristic of benzodiazepines in that it is used appropriately and conservatively, with low liability for abuse. Thus the reported preference for flunitrazepam among opioid abusers seems to be the only way in which flunitrazepam is distinguished from other benzodiazepines; it is unclear what characteristics of the drug may be responsible for this reported preference. The evidence considered in this review indicates that abuse of flunitrazepam in this special population is not associated with any distinctive threats to the health of the general public.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · Applied Ergonomics · doi:10.1016/0003-6870(92)90318-p · Cited by 5,737
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Self-citationPharmacology of Ketamine Isomers in Surgical Patients
White, P. F., Ham, J., Way, W. L., & Trevor, A. (1980) · Anesthesiology · doi:10.1097/00000542-198003000-00008 · Cited by 425
Benzodiazepines, memory and mood: a review
Valerie Curran, H. (1991) · Psychopharmacology · doi:10.1007/bf02316856 · Cited by 401
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Abuse liability of benzodiazepines.
Woods, J. H., Katz, J. L., & Winger, G. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06658-x · Cited by 315
Self-citationPharmacological characterization of benzodiazepine receptors in the brain
Braestrup, C., & Squires, R. F. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90085-7 · Cited by 280
The Validity of Methadone Clients' Self-Reported Drug Use
Magura, S., Goldsmith, D., Casriel, C., Goldstein, P. J., & Lipton, D. S. (1987) · International Journal of the Addictions · doi:10.3109/10826088709027454 · Cited by 213
Rebound Insomnia and Rebound Anxiety: A Review
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (2008) · Pharmacology · doi:10.1159/000137794 · Cited by 198
Cited by
Postmortem toxicology of drugs of abuse
Drummer, O. H. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2004.02.013 · Cited by 302
Residual Effects of Hypnotics: Epidemiology and Clinical Implications
Vermeeren, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00003 · Cited by 277
Behavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
Metadata
- Authors
- Woods, J. H., & Winger, G.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1997-06
- Volume
- 17
- Issue
- 3 Suppl 2
- Pages
- 1S-57S
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2324986561
- Cited by
- 255
- References
- 100
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abuse Liability of Flunitrazepam. https://app.cochat.ai/papers/10.1097/00004714-199706001-00001
- The paper
- Woods, J. H., & Winger, G. (1997). Abuse Liability of Flunitrazepam. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199706001-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.